根据《上市公司独立董事管理办法》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等要求，中金 辐照股份有限公司（以下简称"公司"）董事会就公司在任 独立董事靳云飞、胡锡云、郁红祥的独立性情况进行评估并 出具如下专项意见： 2025 年 4 月 29 日 经核查独立董事靳云飞、胡锡云、郁红祥的任职经历以 及签署的相关自查文件，上述人员未在公司担任除独立董事 以外的任何职务，也未在公司主要股东公司担任任何职务， 与公司以及主要股东之间不存在利害关系或其他可能妨碍 其进行独立客观判断的关系，因此，公司独立董事符合《上 市公司独立董事管理办法》《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》中对独立董事独立性的相关 要求。 中金辐照股份有限公司董事会 中金辐照股份有限公司董事会 对独立董事独立性评估的专项意见 ...

中金辐照股份有限公司 2024 年度独立董事述职报告 述职人：郁红祥 本人郁红祥，1966 年出生，中共党员，法学硕士，一级 律师。历任唐山钢铁集团公司法律顾问，河北省唐山市中级 人民法院助理审判员、审判员、执行员、庭长，河北鸿翔律 师事务所主任、律师，百川股份有限公司独立董事，唐山金 融控股集团公司外部董事等。2023 年 9 月至今任本公司独立 董事。 二、独立董事履职情况 （一）出席董事会、股东会情况 1 / 5 2024 年，公司召开了 10 次董事会和 3 次股东会，本人 均出席了上述会议，认真履行了独立董事的义务，没有缺席、 没有委托他人出席或连续两次未亲自出席会议的情况。本着 勤勉尽责的态度，本人认真审阅董事会会议审议的相关材 料，积极参与议案讨论，依法表决，充分发挥独立董事的作 用。在股东会召开前，本人对需提交股东会审议的各项议案 均进行认真审阅，力求对全体股东负责。公司董事会和股东 会的召集和召开程序符合相关要求，重大经营决策事项和其 他重大事项方面均履行了相关审批程序，合法有效，未损害 股东，特别是中小股东的利益。本人对公司董事会的各项议 案均投了赞成票，无提出异议、反对或弃权的情形。 （ ...

中金辐照股份有限公司 2024 年度独立董事述职报告 述职人：胡锡云 本人作为中金辐照股份有限公司（以下简称公司）第四 届董事会独立董事，严格按照《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司独立董事管理办法》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等相关法律法规、规范性文件以及《公司 章程》《公司独立董事工作制度》等相关规定和要求，本着 对全体股东负责的态度，勤勉、忠实地履行独立董事职责， 认真审议董事会各项议案， 充分发挥了独立董事及各专业 委员会的作用，切实维护了公司和全体股东的利益。现将本 人 2024 年工作情况报告如下： 一、独立董事基本情况 本人胡锡云，1963 年出生，大学学历，研究员级高级会 计师、中国注册会计师。历任北京航天新概念软件有限公司 财务经理、财务总监，北京神舟航天软件技术有限公司财务 总监，中国航天空气动力技术研究院总会计师、航天彩虹 （SZ.002389）董事。2023 年 9 月至今任本公司独立董事。 二、独立董事履职情况 （一）出席董事会、 股东会情况 1 / 6 2024 年，公司召开了 10 次董事会和 3 次股东会 ...

Financial Performance - The company's revenue for Q1 2025 was ¥85,631,926.03, representing a 2.40% increase compared to ¥83,621,422.72 in the same period last year[4] - Net profit attributable to shareholders decreased by 13.52% to ¥25,801,991.28 from ¥29,836,447.36 year-on-year[4] - Basic and diluted earnings per share decreased by 13.54% to ¥0.0977 from ¥0.1130 in the same period last year[4] - The company's net profit for the current period is ¥26,413,668.98, a decrease of 14.4% compared to ¥30,804,107.18 in the previous period[15] - The total profit for the current period is ¥30,864,051.64, down from ¥36,145,484.91, reflecting a decline of 14.7%[15] - Operating profit decreased to ¥30,801,354.72 from ¥36,229,770.47, representing a decline of 15.0%[15] - The total comprehensive income attributable to the parent company is ¥25,801,991.28, down from ¥29,836,447.36, a decrease of 13.5%[15] Cash Flow and Investments - The net cash flow from operating activities fell by 27.36% to ¥30,783,675.88, down from ¥42,380,496.25 in the previous year[4] - The company incurred a net cash outflow from investing activities of ¥100,040,776.11, compared to a net outflow of ¥32,968,882.54 in the previous period[17] - The company received cash from operating activities totaling ¥85,147,796.26, a decrease of 7.9% from ¥92,029,397.07 in the previous period[17] Assets and Liabilities - Total assets increased by 2.15% to ¥1,169,205,425.89 compared to ¥1,144,613,365.91 at the end of the previous year[4] - Total liabilities decreased slightly to ¥153,639,659.29 from ¥155,461,268.29, a reduction of 1.17%[12] - The company's cash and cash equivalents decreased to ¥244,125,687.67 from ¥313,835,255.62, a decline of 22.14%[11] - Cash and cash equivalents at the end of the period decreased to ¥244,125,687.67 from ¥362,109,171.63, a decline of 32.6%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,079[7] - The largest shareholder, China National Gold Group Corporation, holds 54.20% of the shares[7] - Shareholders' equity attributable to the parent company rose by 2.72% to ¥974,270,333.15 from ¥948,468,341.87 at the end of the previous year[4] - The total equity attributable to shareholders rose to ¥974,270,333.15, an increase of 2.84% from ¥948,468,341.87[13] Operating Costs and Expenses - Total operating costs amounted to ¥54,492,699.21, up 13.41% from ¥48,064,108.10 in the prior period[14] - Research and development expenses increased to ¥7,091,505.96, reflecting a rise of 30.73% from ¥5,430,514.21 year-over-year[14] - The company reported a net credit impairment loss of ¥577,169.39, worsening from a loss of ¥216,521.40 in the previous period[14] - The company’s inventory increased to ¥1,010,540.48, up from ¥466,978.91, reflecting a growth of 116.66%[11] Government Subsidies and Non-Recurring Items - The company received government subsidies amounting to ¥237,165.80 during the reporting period[5] - The company did not report any significant changes in non-recurring gains and losses during the period[5]

Financial Performance - The company's operating revenue for 2024 was CNY 358,512,458.03, representing a 3.99% increase compared to CNY 344,754,344.76 in 2023[19]. - The net profit attributable to shareholders for 2024 was CNY 108,872,277.12, a slight increase of 0.73% from CNY 108,077,920.58 in 2023[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 104,194,976.46, up 1.73% from CNY 102,423,177.89 in 2023[19]. - The net cash flow from operating activities for 2024 was CNY 194,010,811.93, an increase of 2.99% compared to CNY 188,380,816.34 in 2023[19]. - The total assets at the end of 2024 were CNY 1,144,613,365.91, reflecting a 3.85% increase from CNY 1,102,213,048.58 at the end of 2023[19]. - The net assets attributable to shareholders at the end of 2024 were CNY 948,468,341.87, a 3.53% increase from CNY 916,156,614.88 at the end of 2023[19]. - The basic earnings per share for 2024 were CNY 0.4124, up 0.73% from CNY 0.4094 in 2023[19]. - The diluted earnings per share for 2024 were also CNY 0.4124, reflecting the same increase of 0.73% from CNY 0.4094 in 2023[19]. - The weighted average return on equity for 2024 was 11.76%, a decrease of 0.31% from 12.07% in 2023[19]. Business Operations - The company’s primary business includes irradiation technology services, which are the main source of revenue and profit, focusing on sterilization services for medical products, food, and pharmaceuticals[31]. - The company has 120 gamma irradiation devices with a total design source capacity of 190 million curies as of the end of 2023, indicating significant operational scale in the radiation technology application industry[29]. - The company provides sterilization services for food packaging materials, including sterile packaging bags and storage bags, effectively extending shelf life and ensuring quality[37]. - The company has established a medical sterilization supply center, certified by ISO standards, providing reliable sterilization services for reusable medical instruments and surgical packs[41]. - The company’s irradiation technology services have shown an upward trend in profitability due to increasing demand and regional market expansion[44]. - The company has developed customized sterilization solutions based on client needs, utilizing various sterilization methods including gamma, electron beam, and ethylene oxide[47]. Market and Customer Base - The company operates in a rapidly expanding market, with a focus on the development of new technologies and services in the radiation processing sector[30]. - The main customer base consists of large companies with high disinfection and sterilization requirements, leading to stable and increasing demand as their business scales[50]. - The company has established long-term stable partnerships with over 30 Fortune 500 companies, including Johnson & Johnson and Asahi Kasei, enhancing its customer base[62]. - The revenue from irradiation technology services accounted for 92.91% of total revenue, amounting to CNY 333.09 million, which is a 4.99% increase from the previous year[70]. Research and Development - The company has invested in 49 new technology research projects and filed 42 new patents in 2024, enhancing its core technology capabilities[56]. - The company is focused on aligning its research and development efforts with international standards to facilitate market expansion and enhance competitiveness[80]. - The company has completed the development of the sterilization process for obstetric instruments, enhancing the irradiation effect and increasing irradiation business volume[81]. - The company is conducting research on the irradiation of diamonds to produce various colors, aiming to increase market share and economic benefits[81]. Financial Management and Investments - The company has committed investments totaling CNY 48 million, with CNY 19.95 million already invested, achieving a progress rate of 41.56%[99]. - The total investment amount for the reporting period was CNY 27,750,000.00, marking a 100% increase compared to the previous year[90]. - The company reported a net cash flow from financing activities of CNY -69,598,421.19, an improvement of 11.89% compared to CNY -78,989,210.39 in 2023[84]. - The company has established a dedicated fund management system to ensure that raised funds are used specifically for designated projects, enhancing regulatory compliance[198]. Corporate Governance - The company has established various specialized committees within the board to enhance governance and operational efficiency[121]. - The company ensures timely and accurate information disclosure, maintaining transparency with investors through designated media[125]. - The company has conducted its operations in accordance with the Company Law and other relevant regulations, maintaining a high level of corporate governance[118]. - The company has a complete and independent business system, with no reliance on the controlling shareholder for procurement or sales[132]. Social Responsibility and Environmental Management - The company has implemented measures to ensure compliance with environmental regulations, with no administrative penalties reported during the reporting period[184]. - The company actively participated in social responsibility initiatives, including providing 18,000 yuan in aid to underprivileged party members and grassroots workers[186]. - The company has established a robust environmental protection management system to fulfill its ecological responsibilities[185]. - The company reported a total of 20.54 million yuan in consumption assistance to support poverty alleviation efforts[186]. Shareholder Returns and Dividends - The company plans to distribute a cash dividend of 1.46 CNY per 10 shares, totaling 38,544,276.96 CNY for the year 2024[175]. - The total cash dividend represents 100% of the distributable profit of 38,586,512.58 CNY[175]. - The company commits to distributing no less than 10% of the annual distributable profit in cash each year for the next three years[200]. - The board and independent directors will fully discuss and consider shareholder opinions, especially from public and small investors, in profit distribution decisions[200].

一、情况概述 证券代码：300962 证券简称：中金辐照 公告编号：2025-010 中金辐照股份有限公司关于子公司签署搬迁补偿 安置协议及补充协议的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 三、风险提示 本次交易对公司 2025 年或以后年度经营业绩影响视具体收回补偿 款时间及金额来确定，并以会计师事务所审计意见为准。在协议履行过 程中可能因国家政策、合作方履约能力等不可预见的或其它不可抗力因 素，从而影响协议的最终执行情况。公司将密切关注本事项进展情况， 及时履行信息披露义务。敬请广大投资者谨慎投资，关注投资风险。 特此公告。 中金辐照股份有限公司董事会 2025 年 4 月 7 日 因深圳市光明区光明街道白花片区连片产业用地土地整备工作的 需要，中金辐照股份有限公司（以下简称"公司"）的子公司深圳市金 鹏源辐照技术有限公司（以下简称"深圳金鹏源"）位于该片区的房屋、 临时建筑物、构筑物及其他附着物等（包含土地，下同）需进行搬迁。 深圳金鹏源拟与光明街道办、深圳市深业明瑞投资有限公司签署《搬迁 补偿安置协议》及《补充协议》，该事项已经公司第 ...

2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 证券代码：300962 证券简称：中金辐照 公告编号：2025-006 整，没有虚假记载、误导性陈述或重大遗漏。 中金辐照股份有限公司 1.召开时间 现场会议时间：2025 年 2 月 18 日（星期二）下午 14:30 网络投票时间：2025 年 2 月 18 日 其中通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025 年 2 月 18 日 9:15—9:25 ，9:30—11:30 和 13:00—15:00。 特别提示 通过深圳证券交易所互联网投票系统进行投票的时间为 2025 年 2 月 18 日 9:15—15:00 期间的任意时间。 1.本次股东会不存在否决议案的情形。 2.现场会议召开地点 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 5.会议主持人：董事长方中华先生 6.本次会议的召集、召开符合《公司法》等法律、法规和规范性 文件以及《公司章程》的有关规定。 （二）会议出席情况 1.股东出席的总体情况 出席本次股东会现场会议和网络投票表决的股 ...

证券代码：300962 证券简称：中金辐照 公告编号：2025-008 中金辐照股份有限公司 第四届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 中金辐照股份有限公司（以下简称"公司"）于 2025 年 2 月 18 日召开 2025 年第一次临时股东会，补选了三名第四届董 事会非独立董事。为进一步加强董事会专门委员会运作，经全 体董事同意豁免会议通知时间要求，公司同日在总部会议室以 现场结合通讯的方式召开第四届董事会第十六次会议。会议应 参加表决董事 9 名，实际参加表决董事 9 名。会议由董事长方 中华先生主持，公司部分监事和高级管理人员列席会议。会议 的召集、召开和表决程序符合法律、法规及《公司章程》的规 定。 二、董事会会议审议情况 会议经充分讨论后表决，形成如下决议： （一）审议通过《关于调整公司第四届董事会各专门委员 会委员的议案》 董事会同意《关于调整公司第四届董事会各专门委员会委 员的议案》。具体内容详见公司同日披露在巨潮资讯网 (www.cninfo.com.cn)上的《关于调整第四届董事 ...

北京大成（深圳）律师事务所 关于中金辐照股份有限公司 2025 年第一次临时股东会 之 法律意见书 北 京 大 成 （ 深 圳 ） 律 师 事 务 所 www.dacheng.com 深圳市福田区深南大道 1006 号国际创新中心 A 栋 3 层、4、12 层（邮编：518026） 3F&4F&12F, Block A, Shenzhen International Innovation Center, No.1006 Shennan Boulevard, Futian District, Shenzhen, 518026, P.R.China Tel: +86 755 2622 4888/4999 Fax: +86 755 2622 4100/4000 二〇二五年二月 关于中金辐照股份有限公司 2025 年第一次临时股东会之 法律意见书 致：中金辐照股份有限公司 北京大成（深圳）律师事务所（以下简称"本所"）接受中金辐照股份有限 公司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东大会规则》（以下简称" ...

证券代码：300962 证券简称：中金辐照 公告编号：2025-009 中金辐照股份有限公司 关于调整第四届董事会各专门委员会委员的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 中金辐照股份有限公司（以下简称"公司"）于 2025 年 2 月 18 日召开了第四届董事会第十六次会议，审议通过了《关于 调整公司第四届董事会各专门委员会委员的议案》。鉴于公司已 完成第四届董事会部分董事的增补，为进一步加强董事会专门 委员会运作，公司对董事会专门委员会委员进行了调整，调整 后的董事会专门委员会组成情况如下: | 专门委员会 | 委员 | 召集人（主任委员） | | --- | --- | --- | | 战略委员会 | 方中华、鲍海文、盛小莉 | 方中华 | | 审计委员会 | 靳云飞、胡锡云、程国江 | 靳云飞 | | 提名委员会 | 胡锡云、郁红祥、李春海 | 胡锡云 | | 薪酬与考核委员会 | 郁红祥、张冬波、靳云飞 | 郁红祥 | 特此公告。 中金辐照股份有限公司董事会 2025 年 2 月 18 日 ...